No Detail Found!

Effectiveness of Ivermectin among COVID-19 patients: A Randomized Controlled Trial

Author(s)
Muhammad Umar Rawalpindi Medical University, Rawalpindi, Pakistan
Rizwana Shahid Rawalpindi Medical University, Rawalpindi, Pakistan
Muhammad Mujeeb Khan Holy Family Hospital, Rawalpindi, Pakistan
Uzma Hayat Rawalpindi Medical University, Rawalpindi, Pakistan
Ayesha Nadar Holy Family Hospital, Rawalpindi, Pakistan
Sheema Afzal Holy Family Hospital, Rawalpindi, Pakistan
Abstract
To determine the effectiveness of Ivermectin among COVID-19 patients in terms of mortality and biochemical/hematological attributes. Materials & Methods: A Randomized Controlled Trial (RCT) was carried out in the Department of Infectious Diseases (DID) of Holy Family Hospital Rawalpindi in March 2021 through a concurrent parallel study design. Apart from seeking Ethical approval for this research, DID was also licensed by the Drug Regulatory Authority of Pakistan (DRAP) for this trial. A total of 90 PCR-positive COVID-19 patients were enrolled in this study via 1:1 randomization in an experimental and control group without blinding. The control group received Standard of Care (SOC) starting from day 1 while the experimental group was given SOC along with Ivermectin (200µg/kg) for 5 days. Study participants were assessed on days 0, 4, 7, and 10 for general symptoms through physical examination, blood oxygen saturation, and diverse hematological and biochemical indicators in addition to adverse events. Data analysis was done by means of SPSS version 25.0. Mean ± SD for age, length of hospital stay, and time to PCR negativity was calculated. Independent sample t-test was applied to determine the mean difference in age, duration of hospital stay, time to PCR negativity, SpO2, oxygen supply, serum Hemoglobin, TLC, platelet count, Clinical Severity Score (CSS), urea and creatinine levels of both groups. The difference in secondary outcome (expiry/discharge) of both groups was compared using the chisquare test. P-value = 0.05 was considered significant. A 95% Confidence Interval was also computed. Results: Males constituted the majority (56.7%) of our study participants. A statistically insignificant difference in mean age (P = 0.42) and mean length of hospital stay (P= 0.32) between experimental and control group subjects were observed. Mean time to PCR negativity was reported to be significantly less (P= 0.002) in the experimental group. Significant improvement was seen in PCR negativity (P<0.05), mean Clinical Severity Score (CSS) (P=0.02), mean hemoglobin level (P=0.03), and mean platelet count (P=0.03). However, the difference in health outcomes of both groups was also determined to be statistically insignificant (P>0.2, 95% CI (-0.20 - 0.12)). Conclusion: Ivermectin could not be validated as effective in reducing mortality and improving the health outcome in COVID-19 patients.
Publication Details
Page(s) 236-241
Published Journal: Journal of Rawalpindi Medical College, Volume: 26, Issue: 2, Year: 2022

Request the full text from PASTIC

Keywords
Randomized Controlled Trial, Ivermectin, PCR, COVID-19, Clinical Severity Score.
0

Citations

0

Downloads

27

Views